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Purpose. Sex disparities in pediatric leukemia have been previously reported, and male children continue to present with poorer
survival. However, the observed disparities are not fully understood. This current study sought to examine disparities in survival
bythesex,andtodetermineiftumorprognosticfactorsimpactonthesedisparities.PatientsandMethods.W eusedtheS urv eillanc e
Epidemiology and End Results dataset of pediatric leukemia patients (ages 0–19 years) diagnosed in the United States from 1973
to 2006. There were 15,215 patients of whom 8,622 (65.7%) were boys and 6,593 (43.3%) were girls. The Kaplan-Meier survival
estimates, log rank test, and Cox proportional hazard methods were used to assess the data. Results. The overall (both sexes) ﬁve-
year survival rate was 67.9%. Girls had a survival rate of 70.1%, while the rate was 66.3% in boys. Girls had a signiﬁcant 14%
decreased risk of dying relative to boys, hazard ratio (HR) = 0.86, 99% CI = 0.80–0.93. There were signiﬁcant diﬀerences between
boys and girls with respect to tumor cell type, race, age at diagnosis, year of diagnosis, and number of primaries, P<0.001. After
controlling for these factors, the sex diﬀerences in survival persisted, with girls still less likely to die from leukemia compared to
boys, adjusted HR (AHR) = 0.85, 99% CI = 0.72–1.00, P<0.01. Conclusion. In a large population-based pediatric leukemia study,
boys continued to show poorer survival. These disparities were not completely explained by treatment received, tumor prognostic
or socio-demographic factors.
1.Introduction
Leukemia remains the most frequently diagnosed childhood
malignancy in the United States, and while overall survival
has increased, the incidence remains to plateau [1–3]. The
improvement in survival may be due to both the early stage
at diagnosis and advances in therapy [3]. However, despite
overall improvements in survival, one segment of children
still experience poorer survival, mainly male children. In
addition, survival is poorest among black children. This
survival disadvantage of both male sex and black ethnic-
ity/race may be explained by the type of treatment received,
unfavorable biological features, stage of tumor at diagnosis,
age at diagnosis, comorbidity, and availability and timely
access to treatment [1–14].
Even in the era of modern advances in treatment and
protocols (since the early 1960s), male children diagnosed
with and treated for leukemia continue to show poorer
prognosis [3–17]. The observed sex diﬀerentiation in pedi-
atric leukemia survival may be related to tumor prognostic
factors such as the cell type—T cells versus B cells/B cell
precursor. There are no studies to our knowledge that are
both population-based and contain a large sample that have
assessed sex as an independent survival factor. The Surveil-
lance Epidemiology and End Results (SEER) is an example
of a large database that allows for the assessment of the eﬀect
of sex on cancer survival. Because of the limited focus in the
literature on the persistent sex variance in pediatric leukemia
survival, we hypothesized that sex diﬀerences continue to
impact survival, and that this variation may be explained by2 ISRN Oncology
biologic features. We sought in this study to assess the eﬀect
of sex on pediatric leukemia survival using over thirty years
of data from SEER. Further, we sought to examine tumor
prognostic factors that may possibly remove the signiﬁcant
diﬀerence in mortality.
2. Patientsand Methods
The SEER datasets from the 17 registries were used to
examine the impact of sex on survival of patients diagnosed
with leukemia and treated for the disease. While leukemia is
not a homogenous cancer, we wanted to assess the eﬀect of
sex on survival from all leukemias. This approach was taken
to ensure a large sample for this study. From 1973 to 2006,
there were 15,321 children diagnosed with leukemia (clinical
subtypes combined).
2.1. Data Source. We used the SEER database which includes
information from 17 registries. This database is estimated to
represent 26% of the US population. SEER has information
on tumor histology, number of primary tumors, radiation
therapy, surgery, survival status, and survival time but
includes no information on chemotherapy. Demographic
information is available on age at tumor diagnosis, year of
diagnosis, sex, and race. The SEER dataset is known to be
reliableandvalidfortheconductofpopulation-basedstudies
involving cancer in the United States [18–20].
2.2. Diagnosis. Leukemia was ascertained using the Interna-
tional Classiﬁcation of Diseases and Related Health Prob-
lems, 10th revision (ICD-10). The clinical subtypes were also
ascertained using the same classiﬁcation code.
2.3. Study Variables
2.3.1.Sex. SexintheSEERdatasetandforthepurposeofthis
study is a biological construct and refers to the classiﬁcation
of living things, generally as male or female according to
their reproductive organs and functions assigned by their
chromosomes. We treated the male as the reference group
with this dichotomous nominal variable.
2.3.2.Race. TheSEERdatasetcollectsinformationonraceas
(a) white, (b) black, (c) others, and (d) unknown. Because of
thediﬃcultiesinexplaining othersandunknown,wedidnot
stress the latter two groups in the interpretation of the results
in this study.
2.3.3. Age at Diagnosis. We examined the age at diagnosis
of patients and extracted data from all patients 0 to 19
years of age at the time of diagnosis. Age is recorded in
category namely: (a) <1 year, (b) 1–4, (c) 5–9, (d) 10–14,
and (d) 15–19 years. These age categories represent pediatric
malignancies groupings used in most studies and were
adopted for the purpose of this paper.
2.3.4. Year of Diagnosis. This study covered 34 years of data
collected by several SEER registries (9–17 over time). The
details of the SEER registries are available elsewhere [21].
We examined every year for which leukemia was diagnosed
as well as mortality status of the patients. To provide some
insight into the survival of these patients by group of years
of diagnosis, we created ﬁve-year interval categories (except
for the last group, 2003–2006) of the year of diagnosis
(1973–1977, 1978–1982, 1983–1987, 1988–1992, 1993–1997,
1998–2002, and 2003–2006). These categories simulate the
ﬁve-year survival periods commonly used in assessing the
clinical beneﬁts of cancer therapeutics. For the purpose
of the analysis, we treated year of diagnosis as a single
and categorical year in order to examine the patterns of
survival. Because the year of diagnosis may inﬂuence the
treatmentpattern and hence prognosis, as well as reﬂecttime
dependency(time-dependent variable),weusedthis variable
in the stratiﬁed analysis (Stratiﬁed Cox).
2.3.5. Number of Primaries. The SEER dataset collects infor-
mation on the number of primary tumors as (a) 1, (b) 2,
and (c) 3 primaries. For the purpose of this study, we treated
this variable as binary by creating two groups of primaries,
namely,(a)oneprimaryand(b)twoormoreprimaries,with
one primary set as the reference group in the analysis.
2.4. Tumor Cell Types. T h ec e l lt y p eo fl e u k e m i ai sa v a i l a b l e
in the SEER dataset. We extracted information on this var-
iable and used two distinct cell types, namely, T cell and B
cell/B precursor.
This variable was treated as binary, with the T cell as the
reference group.
2.5. Radiation Therapy. The SEER dataset lists information
of radiation therapy in a nominal pattern. Radiation is
grouped into (a) beam radiation (b) combination, meaning
beam radiation with implant or isotopes, (c) radiation NOS,
method, or source not speciﬁed, (d) recommended, but
unknown if administered, (e) refused, and (f) unknown.
Detailed information on the radiation therapy regimen such
as dosage is not available. This variable was dichotomized
into (a) radiation = yes and (b) no radiation = no.
2.6. Survival Time and Status. T h es u r v i v a lt i m ei sl i s t e da s
months from the time of diagnosis to the time death from
any cause. In the dataset, those who did not experience the
event (death) during the followup time were censored. The
followup time is listed as the duration from time of diagnosis
to death from any cause or last day of the availability of
survival information in the SEER registry. Therefore, the
followup time varies, with the earlier diagnosed patients
having longer followup times compared to those diagnosed
later. For example, a patient who was diagnosed with
leukemia in January 1973 and was still alive in 2006 has a
maximum followup time of 408 months (1973–2006: 408
months). The survival status was measured on a binary scale,
with0(zero)forcensoredand1(one)fortheeventorfailure.
2.7. Statistical Analyses. We performed a preanalysis screen-
ing by examining data for missing values. To examine
the association between sex and the study variables, we
used a chi-square statistic. And to assess the eﬀect ofISRN Oncology 3
individual covariates on survival, we utilized the univariable
Cox proportional hazard method and obtained the hazard
ratio (relative risk of dying that reﬂects the magnitude of
the association between covariate and survival) as a point
estimate and 99% conﬁdence interval (CI) as well as the P
value for statistical stability of our point estimate. Because
there are many factors that inﬂuence survival of a cohort
of cancer patients treated for the disease, we examined the
eﬀect of sex in combination with other confounding factors
using the multivariable Cox proportional hazard method.
In this regard, we performed two adjusted models, one
without and the other with tumor cell types, and provided
two results in this study. Further, we performed the same
analyses stratiﬁed by the single year of diagnosis which
allowed us to compare hazard of a given year with the
corresponding year’s baseline hazard. Finally, we used the log
rank test to examine the equality of survival by sex. Also,
we graphically illustrated survival estimates in the overall
g r o u pa sw e l la sb ys e xu s i n gt h eK a p l a n - M e i e rs u r v i v a l
curves and survival proportion curve from the life table.
The signiﬁcance level was 0.01, and all tests were two-tailed.
The Statistical Package for Social Sciences (SPSS), version
17.0, SPSS Inc., Chicago, Illinois and STATA (StataCorp)
version 11.0, College station, TX were used to perform the
analysis.
3. Results
Of the 15,215 children diagnosed with leukemia from 1973
to 2006 in the SEER database, 8622 (56.7%) were boys and
6593 (43.3%) were girls. Table 1(a) presents demographic
and tumor factors by sex. There were no sex diﬀerences by
race, year of diagnosis, and number of primaries, P>0.01.
However,thereweresigniﬁcantdiﬀerencesinageatdiagnosis
(= χ2 49.8(4), P<0.0001) and mortality status (χ2 =
23.6(1), P<0.0001) comparing boys with girls. Similarly,
boys and girls did diﬀer signiﬁcantly with respect to the
radiation therapy received, (χ2 = 23.2(1), P<0.0001). Fur-
ther,therewasastatisticallysigniﬁcantdiﬀerence,comparing
boys with girls with respect to the cell types of leukemia
( Tc e l lv e r s u sBc e l l / Bp r e c u r s o r s ) ,( χ2 = 68.7(1), P<
0.0001). The 5-year overall survival rate was 67.9%, while
the 30-year survival rate was 55.6%. Girls showed a better
5-year survival rate of 70.1%, while their 30-year survival
was 58.0%. Survival was poorer among boys, with a 5-year
survival rate of 66.3%, while their 30-year survival rate was
53.9% (Table 1(b)).
Table 2 shows the factors associated with mortality in
our cohort. In this univariable and crude Cox proportional
hazard model, there was a statistically signiﬁcant diﬀer-
ence in the mortality outcome in children with leukemia,
comparing the two sexes. Relative to boys, girls were 14%
less likely to die from leukemia following the diagnosis
and treatment, hazard ratio (HR = 0.86), 99% Conﬁdence
Interval (CI), 0.82–0.92. Black children did diﬀer from
whites with respect to mortality and were 54% more likely
to experience mortality, HR = 1.54, 99% CI, 1.40–1.69.
Radiation per se did not signiﬁcantly improve survival, but
rather survival was worsened when considering this as a
monotherapy, HR = 0.84, 99% CI = 0.77–0.92, P<. 0001,
implying that children with leukemia who did not receive
radiation but received other treatments were 16% less likely
to have failure or experience the event.
Survivalalsovariedsigniﬁcantlybyageatdiagnosisusing
the standard childhood cancer age grouping. Compared to
children who were less than one year of age, children 1
to 4 years were 72% less likely to die from leukemia, HR
= 0.28, 99% CI, 0.23–0.29. Children 5 to 9 years were
67% less likely to die (HR = 0.33, 99% CI 0.30–0.37).
Children ages 10–14 were 44% less likely to die compared
to the children <1y e a ro fa g e( H R= 0.56, 99% CI 0.50–
0.63). Also, using the dichotomous age grouping in order
to examine the possible eﬀect of estrogen or testosterone,
there was a signiﬁcant diﬀerence in mortality by age at
diagnosis comparing children <1.0–9 years to children 10–
19 years, HR = 2.44, P<0.0001. Mortality experience
did diﬀer signiﬁcantly by year of diagnosis, with mortality
reductionobservedduringthelateryearsofdiagnosisrelative
to former. Using the 5-year interval with 1973–1977 as
the reference year, a signiﬁcant decrease in mortality trend
was observed (P value for trend, <0.001). There was a
signiﬁcant 75% increase in mortality, comparing two or
more primaries to one, and children with two or more
primaries were 75% more likely to die, HR = 1.75, 99% CI =
1.47–2.09.
Inassessingtheconfoundingeﬀectofrace,ageatdiagno-
sis, year of diagnosis, radiation therapy, and the number of
primaries, the association between sex and leukemia mortal-
ity among children persisted, adjusted hazard ratio (AHR) =
0.88, 99% CI = 0.83–0.93. Similarly, after further adjustment
including the cell type of leukemia (T cell versus B cell/B
precursors), the signiﬁcant relationship between sex and
pediatric leukemia survival further persisted, AHR = 0.85,
99% CI 0.72–1.00, P = 0.01. Whereas the radiation treated
as monotherapy did not favor survival, after adjustment
for other covariates with prognostic potentials in pediatric
leukemia, there was a signiﬁcant 21% increased risk of dying
among those who did not receive radiation therapy, AHR
= 1.21, 99% CI 1.10–1.23, P<0.0001 (Table 3). Since the
year of diagnosis is relevant to survival due to its prognostic
eﬀect (improvement in treatment protocol overtime), which
may serve as a time-dependent covariate, and adjustment
by ﬁve-year interval has a likelihood of introducing residual
confounding into the results, we stratiﬁed the analysis by
the year of diagnosis. This approach was taken in order to
compare the hazard of a given year to the baseline hazard
of the same year, thus removing the eﬀect of the year of
diagnosis on the eﬀect of sex on the survival. With this
stratiﬁcation, survival diﬀerence by sex persisted without
leukemia cell type (AHR = 0.86, 99% CI = 0.81–0.94, P =
0.018) and with leukemia cell types (AHR = 0.85, 99% CI =
0.72–1.01, P = 0.018).
Figure 1 illustrates the overall survival curve for pediatric
leukemia patients. The survival curve is demonstrated by
sex with boys showing poorer survival, log rank, P<
0.0001 (Figure 2). Figure 3 shows the 5-year interval overall
survival of pediatric patients with leukemia, while Figure 4
demonstrates the similar time interval for survival by sex.4 ISRN Oncology
Table 1: (a) Study variables characterized by sex of pediatric patients diagnosed with leukemia, 1973–2006. (b) Five-year interval survival
percentage of pediatric leukemia patients overall and by sex.
(a)
Covariates Boys Girls χ2 (df) P value
n (%) n (%)
Race 3.81 (3) 0.28
White 7087 (88.2) 5348 (81.1)
Black 657 (7.6) 555 (8.4)
Others 843 (9.8) 663 (10.1)
Unknown 35 (0.4) 27 (0.4)
Age at diagnosis (yrs) 49.76 (4) <0.0001
<1.0 386 (4.5) 385 (5.8)
1.0−4.0 3411 (39.6) 2650 (40.2)
5.0–9.0 1871 (21.7) 1550 (23.5)
10.0–14.0 1450 (16.8) 1094 (16.5)
15.0−19.0 1504 (17.4) 914 (13.9)
Year of diagnosis 5.72 (6) 0.46
1973–1977 683 (7.9) 488 (7.4)
1978–1982 641 (7.4) 516 (7.8)
1983–1987 711 (8.2) 550 (8.3)
1988–1992 865 (10.0) 661 (10.0)
1993–1998 1290 (15.0) 1005 (15.2)
1999–2002 2167 (25.1) 1720 (26.1)
2003–2006 2265 (26.3) 1653 (25.1)
Number of primaries 3.16 (1) 0.07
1.0 8499 (98.6) 6475 (98.2)
≥ 2.0 123 (1.4) 118 (1.8)
Survival time (months) <0.0001
Median 45.0 51.0
Mean (sd) 79.32 (88.4) 85.87 (93.06)
Mortality status 23.6 (1) <0.0001
Alive 5815 (67.4) 4689 (71.1)
Dead 2807 (32.6) 1904 (28.9)
Radiation 23.2 (1) <0.0001
Yes 1622 (18.8) 1043 (15.8)
No 7000 (81.2) 5550 (84.2)
Abbreviations and notes: sd = standard deviation. The signiﬁcance level is 0.01 (1% type 1 error tolerance).
(b)
Survival percentage by sex
Survival time interval (months) Overall survival (%) Boys (%) Girls (%)
0–60 67.9 66.3 70.1
60–120 63.0 60.9 65.7
120–180 61.0 58.8 63.8
180–240 59.6 57.3 62.6
240–300 58.9 56.6 61.8
300–360 57.1 55.7 60.1
360–420 55.6 53.9 58.0
Notes: the maximum followup time was 408 months. The survival interval for the last row is 360–408 months but presented as 360–420 to meet the ﬁve-year
survival cutoﬀ point.ISRN Oncology 5
Table 2: Mortality associated with sex and other factors in pediatric patients diagnosed with leukemia, 1973–2006.
Covariates Hazard ratio (HR) 99% CI P
Sex
Male 1.00 Ref Ref
Female 0.86 0.80–0.93 <0.0001
Race
White 1.00 Ref Ref
Black 1.54 1.36–1.74 <0.0001
Age at diagnosis (yrs)
<1.0 1.00 Ref Ref
1.0−4.0 0.26 0.22–0.30 <0.0001
5.0–9.0 0.33 0.28–0.39 <0.0001
10.0–14.0 0.56 0.48–0.66 <0.0001
15.0 −19.0 0.89 0.77–1.04 0.05
Number of primaries
1.0 1.00 Ref Ref
≥ 2.0 1.75 1.40–2.20 <0.0001
Beam radiation
Yes 1.00 Ref Ref
No 0.84 0.77–0.92 <0.0001
Notes and abbreviations: the signiﬁcance level was 0.001. CI = conﬁdence interval, ref = reference group or class.
Table 3: Mortality associated with sex in pediatric patients diagnosed with leukemia, 1973–2006.
Covariates AHR 99% CI P
Sex
Boys 1.0 Ref Ref
Girls 0.88 0.81–0.95 <0.0001
Race
White 1.0 Ref Ref
Black 1.47 1.31–1.66 <0.0001
Age at diagnosis (years)
<1.0 1.0 Ref Ref
1.0−4.0 0.24 0.21–0.28 <0.0001
5.0–9.0 0.31 0.26–0.37 <0.0001
10.0–14.0 0.54 0.46–0.62 <0.0001
15.0−19.0 0.83 0.71–0.96 0.001
Year of diagnosis
1973–1977 1.0 Ref Ref
1978–1982 0.70 0.61–0.81 <0.0001
1983–1987 0.57 0.49–0.65 <0.0001
1988–1992 0.40 0.35–0.47 <0.0001
1993–1997 0.36 0.32–0.42 <0.0001
1998–2002 0.30 0.26–0.34 <0.0001
2003–2006 0.27 0.23–0.31 <0.0001
Number of primaries
1.0 1.0 Ref Ref
≥ 2.0 1.32 1.10–1.33 0.002
Radiation
Yes 1.0 Ref Ref
No 1.21 1.10–1.33 <0.0001
Notes and abbreviations: the signiﬁcance level was 0.01. CI = conﬁdence interval. AHR = adjusted hazard ratio, ref = the reference group or class.6 ISRN Oncology
0
0.25
0.5
0.75
1
14789 4376 1844 687 25
Number at risk
0 100 200 300 400
Analysis time
Kaplan-Meier survival estimate
Figure1:Kaplan-Meiersurvivalcurveforallpediatricpatientswith
leukemia, SEER dataset 1973–2006.
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Figure 2: Kaplan-Meier survival curve illustrating distinct survival
of pediatric patients with leukemia by sex, (log rank P<0.0001).
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Figure 3: Overall proportion of pediatric patients with leukemia
surviving by 5-year interval.
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Figure 4: Proportion of pediatric patients with leukemia by sex
surviving, 5-year interval.
4. Discussion
Survival disparity by the sex of the pediatric patient with
leukemia has been observed since the nineteen sixties;
however, what remains to be fully grasped are the factors
responsible for this persisting survival diﬀerence between
boysandgirls.Girlscontinuetodemonstratesurvivaladvan-
tage relative to boys. We conducted a survival assessment,
analyzing data spanning a 34-year period (1973–2006) to
examine whether or not sex distinction in pediatric leukemia
survival still exists, as well as whether we can explain survival
variability by sex.
Our assessment has several relevant ﬁndings. First, we
have validated the observed sex disparity in pediatric leu-
kemia survival using a large and long-term dataset. Second,
boys are more likely to show poorer outcome of survival
compared to girls. Third, the crude survival in this cohort
is associated with race, age at diagnosis, year of diagnosis,
number of primaries, and tumor cell type. Finally, survival
diﬀerences by sex are not explained by the diﬀerences in
radiation therapy received, age at tumor diagnosis, year of
diagnosis, race, or tumor cell type.
Studies over the past years [5–17] have repeatedly shown
that after diagnosis of pediatric leukemia, boys present with
poorer survival. In this study, we wanted to see whether
using a large sample and long-term data will help explain
the ongoing variance in leukemia survival comparing boys to
girls. In doing this, we considered factors within the dataset
that might possibly inﬂuence survival in this cohort. After
havingadjustedforthesefactors,wehaveshownthatboysare
more likely to die from leukemia. This ﬁnding is supported
by previous studies [2–4, 8–17].
Pediatric leukemia survival may be associated with the
tumor cell type at diagnosis [22]. The patients with T-cell
leukemia have poorer survival, and in our study, boys were
more likely to have T-cell leukemia. Our ﬁnding supports
previous studies on sex diﬀerences in leukemia prognosis
[22,23].TheleukemiacelltyperemainsinpartanalternativeISRN Oncology 7
explanation to the observed disparity in survival by sex,
since most of the patients who had T-cell type were boys,
and survival was poorer among boys in our study. One
would think, after controlling for these factors, the observed
variance would not persist, but that was not the case in
this dataset. Therefore, there appears to be a biological
explanationbeyondthecelltypeforsexdisparity inpediatric
leukemia survival. It is plausible to suspect XY chromosomal
instability as a possible contribution to abnormal cellular
proliferation, thus resulting in a biologically aggressive
leukemia among male pediatric patients. Also, it might be
possible that testosterone or estrogen may play a small role
in pediatric leukemia. However, in our data, these hormones
used as proxy by categorizing age at diagnosis into two
groups (0–9 versus 10–19 years) and examining survival
by sex while adjusting for the eﬀect of these hormones
did not alter the eﬀect of sex on survival. However, our
data showed in the univariable Cox regression model that
children aged 10–19 years were two times as likely to
experience mortality compared to children aged 0–9 years.
Nevertheless, it is not clear if this observation is explained
by the eﬀect of hormones on tumor prognosis, and if this
is the case, which hormone, estrogen, or testosterone might
be causing this eﬀect. Since tumor cell type signiﬁcantly
inﬂuenced survival, and older children were more likely to
be diagnosed with T-cell type which is associated with poor
survival, this may explain in part why survival was poorer
for children aged 10–19 years at the time of tumor diagnosis.
The Mantel-Haenszel stratiﬁcation analysis performed to
examine the sex diﬀerence on the eﬀect of dichotomous age
group at diagnosis showed poorer survival for boys in the
age group of 10–19 years relative to girls in the same age
group.
Racial/ethnic variation in pediatric leukemia survival
has been shown by previous ﬁndings [24–26]. Our results
support previous studies, since we found race to be an in-
dependent predictor of survival in pediatric leukemia. The
blackchildrenwithleukemiapresentedwithhighermortality
relative to their white counterparts. Indeed, our study found
that black children were 54% more likely to die from
leukemia compared to white children. Race is a diﬃcult
concept to explain. Information on race and the factors de-
ﬁning it remains unclear. Whereas we have observed ra-
cial variation in pediatric leukemia survival, it is not very
clear what this translates to in terms of cancer survival.
Therefore, the racial variation observed in this dataset may
be related to racial disparities in socioeconomic factors, life-
style variables, or biology, factors which were not available in
the dataset used for this study.
We have also shown that radiation as a monotherapy did
not improve survival of children diagnosed with leukemia
and treated for the disease. This ﬁnding supports the
limitation of monotherapy in pediatric cancer therapeu-
tics. However, our study also showed that in combination
with other therapies, radiation therapy provides a survival
advantage. This is veriﬁed based on ﬁndings using the
multivariable model, which allows us to simultaneously
adjust for the eﬀect of other covariates, while examining the
eﬀect of radiation therapy on survival of these children.
Survival varied signiﬁcantly by the age at diagnosis. Chil-
dren less than one year of age had the poorest survival, which
may be explained by their immature immune system. The
immune responsiveness to tumor antigen has been well doc-
umented [27]. Children diagnosed with leukemia who are
less than six months of age are less likely to mount immune
response to the tumor-speciﬁc antigen, and therefore, the
immunologic surveillance of malignancy is signiﬁcantly
compromised at this age group [28]. It also appears that the
older the children, the better the survival, but this was not a
linear trend since the best survival was seen among children
aged 1–4 years.
Children continue to be diagnosed with more than one
primary tumor. For example, children with retinoblastoma
have an increased risk of developing leukemia [29]. Children
with more than one primary tumor were shown in our
study to have poorer survival. It is plausible that survival was
poorer among children with more than one primary. This
might be due in part to the interaction in treatment (radi-
ation, chemotherapy) that may further lower the immune
responsiveness to the tumor, and thereby decrease survival
among children with more than one primary. However, drug
interaction in pediatric cancer is not very well understood,
given the present stage of our knowledge in pediatric
cancer therapeutics, and the potentials for adverse survival
remains.
The year of diagnosis has been shown in our study to
signiﬁcantly inﬂuence leukemia survival. We examined this
variable using 5-year intervals and found that children diag-
nosed during the early years of SEER registry (1973−1997)
had poorer survival relative to those diagnosed in later years
of registry. Indeed, we observed a trend in the 5-year of
diagnosis groupings. Because the year of diagnosis inﬂuences
thesurvivalduetothechangesinthetreatmentprotocolover
time, and the observation that the year of diagnosis is a time-
dependent variable, we stratiﬁed the analysis by the year of
diagnosis and found signiﬁcant variation in survival by sex.
This observation may very well be explained by the birth
cohort eﬀect or improvement in the treatment protocol. We
could have assessed the birth cohort and the treatment eﬀect
as possible explanations for the trend in survival by year of
diagnosis; however, the SEER data set is limited with respect
tosometreatments,namely,chemotherapy,aswellasthelack
of information regarding known eﬀective treatments such as
surgery.
The nature of entry into a cohort in a survival study
is very important in the examination of the survival time
(median, mean, and percentile). The SEER dataset used in
this survival study obtained information from newly diag-
nosed pediatric patients with leukemia, some who entered
the study at the beginning of the dataset creation (1973),
and some who entered the study at the time where the most
recent data on pediatric leukemia is available at the National
Cancer Institute (2006). Likewise, data in this study included
those who were diagnosed and died before the beginning
of the survival time in this study. With this variability, it is
diﬃcult to estimate the precise median survival time for the
overall cohort as well as the sex cohort. We estimated the
survival percentage in this study based on our understanding8 ISRN Oncology
that the proportion of those who died at the entry diﬀers
from those who died towards the end of the study due
precisely to the variation in the length of followup. Whereas
our description of survival time in this study allows one
to understand the eﬀect of sex and other covariates on
survival, this description should be interpreted with caution
due to this signiﬁcant variation in the length of followup
in the SEER dataset. In addition, due to this variability, we
performedstratiﬁedanalysisbytheyearofdiagnosis inorder
to remove this imbalance and to present a valid hazard of
dying, given the eﬀect of sex.
Despite the strength of this study, given its potential to
clearly determine the eﬀect of sex on pediatric leukemia
survival, there are a few limitations. First, our analyses are
based on a retrospective design inspite of a well-organized,
valid, and reliable SEER dataset. However, such dataset has
a tendency for missing information on important variables.
For example, we were not able to have substantial infor-
mation on the radiation status of most of the patients.
In addition, there was no information on chemotherapy
received for leukemia. Secondly, because we used preexisting
data, we were not able to assess or address confounding
variables known to inﬂuence pediatric leukemia survival.
Therefore, this study may be inﬂuenced by unmeasured and
unknown confounding. And despite controlling for age at
diagnosis, number of primaries, year of diagnosis, radiation,
and race, it is possible that residual confounding might have
inﬂuenced our results. However, it is highly unlikely that our
ﬁndings of survival variability by sex in pediatric leukemia
are driven solely by these confounding (unmeasured and
residual), since no matter how sophisticated a model used
to control for confounding, residual confounding is likely to
inﬂuence the result of epidemiologic study [23].
5. Conclusions
In summary, this study showed a survival diﬀerence by sex
of children with leukemia after controlling for the eﬀect of
race,ageatdiagnosis,yearofdiagnosis,numberofprimaries,
and tumor cell type, which were the factors that inﬂuenced
survival. Therefore, given the persisting sex diﬀerences in
pediatric leukemia survival in this large dataset and long-
term assessment, there is need to further examine biological
variability in leukemia including sex variance in response to
treatment.
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